ZenNews› Health› AI Virus Design Splits U.S. Biotech Funding Calcu… Health AI Virus Design Splits U.S. Biotech Funding Calculus Synthetic pathogen breakthroughs force investors to weigh profit against biosafety risk By Oliver Walsh Aug 11, 2026 1 min read Updated: Aug 11, 2026 Share Share X Facebook WhatsApp Copy link How do you feel about this? 🔥 0 😲 0 🤔 0 👍 0 😢 0 Health Virus Design Splits Biotech O Oliver Walsh Health & Climate Oliver Walsh analyses medical research, US health policy and climate science. You might also like › Health AI-Designed Virus Research Splits U.S. Biosecurity Funding Debate 17 Aug 2026 Health FDA's New Weight-Loss Pill Reshapes U.S. Obesity Drug Market 14 Aug 2026 Health AI-Built Viruses Put U.S. Biosafety Oversight to the Test 17 Aug 2026 Health Weekly Insulin Shot Fuels U.S. Push to Simplify Diabetes Care 20 Aug 2026 Health AI-Designed Viruses Prompt Senate Biosecurity Alarm 06 Aug 2026 Health Thermostable Vaccines Reshape U.S. Cold Chain Spending Bets 06 Aug 2026 Also interesting › World Indiana Power Crisis Exposes U.S. Grid Inequity Fault Lines Just now Tech Meta Child Addiction Verdict Nears as Science Gap Widens Just now Sports Pegula's Cincinnati Run Puts U.S. Women's Tennis on Notice 9 hrs ago US Politics Military Paper Firing Tests Press Shield in Pentagon Chain 10 hrs ago More in Health › Health Weekly Insulin Shot Fuels U.S. Push to Simplify Diabetes Care 20 Aug 2026 Health AI-Built Viruses Put U.S. Biosafety Oversight to the Test 17 Aug 2026 Health AI-Designed Virus Research Splits U.S. Biosecurity Funding Debate 17 Aug 2026 Health FDA's New Weight-Loss Pill Reshapes U.S. Obesity Drug Market 14 Aug 2026 ← Health AI-Designed Viruses Prompt Senate Biosecurity Alarm Health → FDA's New Weight-Loss Pill Reshapes U.S. Obesity Drug Market
